Feasibility of a 3-step protocol of wheat oral immunotherapy in children with severe wheat allergy.
Child
Food allergy
Oral immunotherapy
Wheat
Wheat hypersensitivity
Journal
Asia Pacific allergy
ISSN: 2233-8276
Titre abrégé: Asia Pac Allergy
Pays: Netherlands
ID NLM: 101561954
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
08
03
2020
accepted:
19
10
2020
entrez:
12
11
2020
pubmed:
13
11
2020
medline:
13
11
2020
Statut:
epublish
Résumé
Wheat allergy is not an uncommon event among Thai children. Despite strict avoidance, some patients developed reactions after accidental exposure to minute amount of wheat and thus disturbed their quality of life. Wheat oral immunotherapy (OIT) has been reported to be an alternative treatment for such patients. We designed a new 3-step wheat OIT protocol for treatment of severe wheat allergy in Thai patients. The feasibility of the protocol is evaluated and is reported here in this paper. We retrospectively reviewed medical records of 26 patients who had undergone wheat OIT during a 30-month period. The 3-step protocol consisted of an initial phase of double-blind, placebo-controlled food challenge (DBPCFC) and initiation of OIT, a build-up phase, and a maintenance phase. Patient retention in the protocol was the main outcome for this feasibility study. Adverse effects during OIT were recorded. Correlation between serum specific IgE (SpIgE) to wheat and eliciting dose in phase I was determined. Fourteen females and 12 males with a median age of 6 years were studied. Their median age when wheat allergy began was 8 months. Median SpIgE to wheat was high (198 kU The new 3-step wheat OIT protocol was feasible in these highly wheat-sensitized patients. Despite a high retention rate, a high rate of adverse effects was observed both during DBPCFC and build-up phases.
Sections du résumé
BACKGROUND
BACKGROUND
Wheat allergy is not an uncommon event among Thai children. Despite strict avoidance, some patients developed reactions after accidental exposure to minute amount of wheat and thus disturbed their quality of life. Wheat oral immunotherapy (OIT) has been reported to be an alternative treatment for such patients.
OBJECTIVE
OBJECTIVE
We designed a new 3-step wheat OIT protocol for treatment of severe wheat allergy in Thai patients. The feasibility of the protocol is evaluated and is reported here in this paper.
METHODS
METHODS
We retrospectively reviewed medical records of 26 patients who had undergone wheat OIT during a 30-month period. The 3-step protocol consisted of an initial phase of double-blind, placebo-controlled food challenge (DBPCFC) and initiation of OIT, a build-up phase, and a maintenance phase. Patient retention in the protocol was the main outcome for this feasibility study. Adverse effects during OIT were recorded. Correlation between serum specific IgE (SpIgE) to wheat and eliciting dose in phase I was determined.
RESULTS
RESULTS
Fourteen females and 12 males with a median age of 6 years were studied. Their median age when wheat allergy began was 8 months. Median SpIgE to wheat was high (198 kU
CONCLUSION
CONCLUSIONS
The new 3-step wheat OIT protocol was feasible in these highly wheat-sensitized patients. Despite a high retention rate, a high rate of adverse effects was observed both during DBPCFC and build-up phases.
Identifiants
pubmed: 33178563
doi: 10.5415/apallergy.2020.10.e38
pii: 2020100405
pmc: PMC7610086
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e38Informations de copyright
Copyright © 2020. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors have no financial conflicts of interest.
Références
J Allergy Clin Immunol. 2020 Apr;145(4):1292-1295.e1
pubmed: 31881232
Iran J Allergy Asthma Immunol. 2016 Dec;15(6):525-535
pubmed: 28129685
Allergy Asthma Immunol Res. 2016 Nov;8(6):535-40
pubmed: 27582405
Asia Pac Allergy. 2014 Jul;4(3):180-3
pubmed: 25097855
Pediatr Allergy Immunol. 2019 Nov;30(7):681-688
pubmed: 31220363
Asian Pac J Allergy Immunol. 2020 Mar 29;:
pubmed: 32247307
J Allergy Clin Immunol. 2015 Oct;136(4):1131-3.e7
pubmed: 26319801
Acta Paediatr. 2018 May;107(5):861-870
pubmed: 29345001
J Emerg Med. 2005 May;28(4):381-8
pubmed: 15837017
Int Arch Allergy Immunol. 2018;176(3-4):249-254
pubmed: 29870996
Asia Pac Allergy. 2013 Jan;3(1):29-34
pubmed: 23403810
J Allergy Clin Immunol. 2019 Feb;143(2):651-661.e9
pubmed: 30389226
Allergol Int. 2016 Jan;65(1):82-7
pubmed: 26666490
Allergy Asthma Immunol Res. 2016 Jul;8(4):353-61
pubmed: 27126729
Asian Pac J Allergy Immunol. 2017 Jun;35(2):113-117
pubmed: 27543738
Asian Pac J Allergy Immunol. 2016 Jun;34(2):153-8
pubmed: 27007837
Pediatr Allergy Immunol. 2008 May;19(3):270-4
pubmed: 18397411
Clin Exp Dermatol. 2020 Jan;45(1):56-62
pubmed: 31267575
Ann Allergy Asthma Immunol. 2009 May;102(5):410-5
pubmed: 19492663
J Allergy Clin Immunol Pract. 2017 Jan - Feb;5(1):58-62.e5
pubmed: 28065342
J Allergy Clin Immunol Pract. 2020 Jan;8(1):371-374.e5
pubmed: 31520842
J Investig Allergol Clin Immunol. 2014;24(4):240-8
pubmed: 25219106
J Allergy Clin Immunol. 2012 Dec;130(6):1260-74
pubmed: 23195525